Search the cosmetic ingredient literature for peptides and grey hair and the database returns three papers. Two of them are about a spider.
Diguetia canities is a weaving spider whose venom was characterised in the 1990s, and "canities" is also the medical word for hair going grey. Two insecticidal-peptide papers therefore sit inside any naive count of the anti-greying peptide literature. Remove them and the peer-reviewed record joining peptides to hair greying in a title or abstract is one paper. Against that, the database holds 642 records on greying and canities as a subject.
That single paper is worth reading carefully, because it is the entire scientific foundation of a product category.
The one study
Efficacy of an agonist of α-MSH, the palmitoyl tetrapeptide-20, in hair pigmentation appeared in the International Journal of Cosmetic Science in 2018, written by authors at Laboratoire BIO-EC, the CNRS, Ales Groupe, Inserm and IFF-Lucas Meyer Cosmetics — the last being the ingredient's manufacturer.
The laboratory work is substantial. In human follicle dermal papilla cells, the peptide increased catalase expression and reduced intracellular hydrogen peroxide by 30%. It raised melanin production, with increased expression of MC1-R, TRP-1 and Melan-A, and reduced expression of ASIP. In micro-dissected human hair follicles cultured outside the body, the same markers moved.
Then comes the clinical section, and this is where a reader has to slow down. Fifteen male volunteers with premature canities applied a lotion containing 10 ppm of the peptide daily for three months. The measurement taken at the end was MC1-R protein expression in plucked hairs.
Not the colour of the hair. Not a photograph graded by a blinded reviewer. Not the proportion of pigmented hairs. A receptor protein, in hairs pulled from the scalp, confirming that the mechanism demonstrated in the dish also moved in people.
That is a legitimate and useful experiment. It is not a demonstration that hair went less grey, and the paper does not claim it is: its conclusion is that the results suggest a potential cosmetic application. Between that sentence and a product page promising to slow greying sits an unrun trial.
The other peptide, and its single case
The second molecule marketed for greying is acetyl hexapeptide-1, sold under the trade name Melitane. It is also an α-MSH agonist, so the mechanistic story is the same one.
Its entire clinical literature in PubMed is a case report of one patient: a 14-year-old girl with premature hair greying treated with topical Melitane 5% together with oral hair supplements, published in the Indian Journal of Pharmacology in 2019 by a dermatology clinic in Surat. The authors report improvement in hair colour.
A single-patient case report is the weakest study design there is — no control, no blinding, no comparison — and here the treatment was a combination, so even the direction of any effect cannot be assigned to the peptide rather than to the supplements. The report is honest about what it is; the difficulty is that it is the only clinical publication the ingredient has.
What the evidence actually supports
| Claim | Evidence located | Strength |
|---|---|---|
| α-MSH agonist peptides increase melanin production in cultured cells | Int J Cosmet Sci 2018, in vitro and ex vivo | Demonstrated in the laboratory |
| They reduce oxidative stress markers in follicle cells | Same paper: catalase up, hydrogen peroxide down 30% | Demonstrated in the laboratory |
| The mechanism can be detected in people using the lotion | Same paper: MC1-R expression in plucked hairs, 15 men, 3 months | Demonstrated, on a marker |
| Applying them makes hair less grey | No trial located | Not established |
The category's problem is not that the science is fake. The mechanism is real, hydrogen peroxide accumulation in the greying follicle is genuinely well studied, and the peptide moved the markers it was designed to move. The problem is that the last row of that table — the only row a shopper cares about — has never been filled in, and the marketing is written as though it has.
The naming trap on the label
Ingredient lists make this category unusually easy to get wrong. The pigmentation peptide is palmitoyl tetrapeptide-20. A far more common cosmetic ingredient, palmitoyl tetrapeptide-7, differs by one digit, is used for entirely different reasons in facial products, and has no greying literature whatsoever.
The same pattern recurs across this whole field: Matrixyl is palmitoyl pentapeptide-4, while palmitoyl tripeptide-1 is a different molecule sold in a differently numbered blend. A claim attached to one number does not transfer to its neighbours, and a product that names a peptide with a greying claim is worth checking digit by digit.
Copper, tyrosinase and a reasonable-sounding leap
Copper peptides come up in greying discussions because copper is a cofactor for tyrosinase, the enzyme that begins melanin synthesis. The inference — more copper at the follicle, more pigment — is the kind that sounds like biochemistry and functions as marketing.
Nothing in the greying searches above returns a trial of GHK-Cu for hair colour. The copper-peptide hair studies that do exist measure growth endpoints, and as our copper peptides page sets out, even the skin evidence for topical GHK-Cu is thinner than its reputation, with the open question of how much crosses intact skin still unresolved in the 2024 review literature.
What is known about greying itself
The absence of peptide evidence does not mean nothing is known. Greying is one of the better-characterised parts of hair biology: melanocyte stem cells in the follicle bulge are progressively depleted, oxidative stress including hydrogen peroxide accumulation damages the pigment machinery, and catalase activity declines with age. Genetics dominates the timing.
That is the same mechanism the 2018 paper is built on, which is precisely why the peptide is a reasonable thing to test. The honest position is that it has been tested on markers and not yet on hair. When a company runs a photographic, placebo-controlled trial of an α-MSH peptide against premature greying, that will be a genuinely new result, and the first one this category has.
Until then, the record is one paper on 15 men measured on a receptor, one case report on one teenager taking two products at once, and two papers about spider venom that happened to share a word.
Sources
- Almeida Scalvino S et al. Efficacy of an agonist of α-MSH, the palmitoyl tetrapeptide-20, in hair pigmentation. Int J Cosmet Sci 2018;40(5):516-524.
- Sakhiya JJ et al. Case report on premature hair graying treated with Melitane 5% and oral hair supplements. Indian J Pharmacol 2019;51(5):346-349.
- Insecticidal peptides from Diguetia canities: Toxicon 1996 and Insect Biochem Mol Biol 1995 — the two records that inflate a naive count.
- PubMed record counts run 2026-09-10 with the queries printed above.
